First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
Nicholas S, Correa-Rotter R, Desai N, Guo L, Navaneethan S, Pantalone K, Wanner C, Hamacher S, Fatoba S, Horvat-Broecker A, Garreta-Rufas A, Gay A, Merz M, Wheeler D. First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting. Journal Of Nephrology 2024, 37: 2223-2232. PMID: 39340711, PMCID: PMC11649709, DOI: 10.1007/s40620-024-02070-y.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseMedian Follow-UpNon-interventional study of patientsNon-steroidal mineralocorticoid receptor antagonistPrimary care settingMonths median follow-upTreatment-emergent adverse eventsSodium-glucose cotransporter 2 inhibitorsInterim analysisAngiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor BlockersCKD risk categoryAssociated with type 2 diabetesMineralocorticoid receptor antagonistsClinical practiceInhibitors/angiotensin receptor blockersPhase 4 studyNon-interventional studyStudy of patientsCare settingsRoutine careType 2 diabetesFinerenone treatmentTreatment discontinuationReceptor antagonistReceptor blockers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply